Allogenic CAR-T cell therapy without gene editing

Allogenic CAR-T cell therapy without gene editing

Tuesday, November 3, 2020 1:00 PM to 1:25 PM · 25 min. (Africa/Abidjan)
World Immunotherapy Congress
Cellular immunotherapy
Presentation

Information

  • Celyad utilizes two technologies based on non-gene edited approaches to modulate the T-cell receptor (TCR) complex to generate allogeneic CAR-T therapies.
  • The first approach utilizes our TCR-inhibitor molecule (TIM) and is tailored to our NKG2D-based CAR-T clinical candidate CYAD-101
  • The second approach leverages shRNA technology to knockdown the expression of the TCR on the surface of the T-cell and is used in CYAD-200 series

Laure Twyffels, Research & Development Manager, Celyad Oncology

Axion BioSystemsAxion BioSystems is a global leader manufacturer and provider of microelectrode-based technologies for the life sciences market. Axion solutions for cell analysis allow label-free, non-invasive recordings for long-term monitoring in multiwell plate format. Easy to set-up and use, Axion platforms include software packages delivering real-time and automated data analysis. Axion Maestro Z is the world’s most advanced impedance-based real-time cell analysis platform. Over minutes or weeks, it allows gaining unprecedented access to the kinetics of your biology. Straightforward and easy to use, any researcher can now track immune cell-mediated killing in a 96-well plate in real time. Applications include: ·        Cell Proliferation and Viability ·        Cytotoxicity, Chemotherapy ·        Immune Cell-Mediated Cytotoxicity, Cancer Immunotherapy, Immuno-oncology ·        Receptor-mediated signaling ·        Cancer cell migration axionbiosystems.com Maestro Z

Log in

See all the content and easy-to-use features by logging in or registering!